Presently used markers of infection in bronchiectasis are inadequate to judge stability or make decisions about antibiotic treatment during bacterial exacerbations. Procalcitonin (PCT) is a new marker that has been used in community-acquired pneumonia and promises to allow much more specific and sensitive monitoring of patients with bacterial infections. This is the first study assessing its use in bronchiectasis. Thirty-eight consecutive inpatients and 63 consecutive outpatients were included in the study. All patients had PCT, other inflammatory markers, and a symptom score recorded. Inpatients had these values repeated at day 5 and 10 of their stay, while receiving intravenous antibiotics. Outpatients: PCT levels were generally low in the outpatient group. PCT was significantly correlated to C-reactive protein. Higher levels were associated with increased symptoms (P = 0.09) and an increased likelihood of antibiotic prescription (P = 0.007). Inpatients: As a group, inflammatory markers were significantly higher than in the outpatient group (P = 0.007). There was no correlation between the levels of PCT and the other inflammatory markers. PCT concentrations were generally low (as with other markers), which may reflect mucosal infection. Larger studies are needed, but PCT seems unlikely to be able to guide treatment of an exacerbation in bronchiectasis. PCT may offer more promise as a measure of stability. Chronic Respiratory Disease 2008; 5: 155-160
Introduction
Bronchiectasis is a chronic lung disease characterized by dilated bronchial walls leading to poor mucus clearance and a predisposition to lower respiratory tract infections. 1 Clinical presentation is with recurrent or chronic bacterial airway infections, chronic cough, and mucus production. Repeated infections lead to increased morbidity and also further damage and progression of disease. 2 Management of bronchiectasis involves investigation to identify treatable causes, and there is a strong focus on prevention of exacerbations by good physiotherapy. The use of antibiotics is also central in this condition. Good quality randomized controlled trials are sparse in bronchiectasis, and much of the treatment is based on expert opinion and extrapolation from the management of other respiratory conditions. With regards to antibiotic management, few would argue against the use of antibiotics for an acute infective exacerbation. How-ever, accurately defining this population and the length of antibiotic treatment is less wellcharacterized. Part of the problem is that presently used systemic markers for bacterial infection are limited by poor specificity and sensitivity. 3 Patients with exacerbations of bronchiectasis are often treated for acute infective episodes based on history, with normal inflammatory markers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood count (WBC). The length of intravenous treatment is also chosen without definitive physiological or serological markers and is historically for 10 days.
Another issue in bronchiectasis management is whether significant benefit can be gained by the use of long-term prophylactic antibiotics in certain groups of patients. There are several theoretical advantages to antibiotic use in the stable condition. Long-term antibiotic use may reduce the bacterial load in the respiratory tract. It is believed that exacerbations are the result of an upset in the balance between the host defense and the local pathogen load, and this reduction may make infective exacerbations less likely to occur. 2 In addition, the vicious circle hypothesis in bronchiectasis 4 suggests that increased microbial load leads to inflammation and further tissue damage. 5, 6 This inflammation can be reduced by long-term antibiotics, particularly the macrolides that have an anti-inflammatory component in addition to their antibacterial effects. [7] [8] [9] However, studies on the use of prophylactic antibiotics have been small and inconclusive. A recent Cochrane meta-analysis concluded that there may be a small benefit for the use of prophylactic antibiotics in reducing sputum volume and purulence, but there was no evidence for an effect on the progression of the condition. 10 The evidence is much greater in cystic fibrosis, [11] [12] [13] and it is clear that some subgroups of patients with bronchiectasis may derive a clearer benefit from a prophylactic antibiotic approach. Defining this population would also be a great advance in the management of the condition.
Procalcitonin (PCT) is a new marker of infection that has shown promise in other conditions. 14 PCT, a precursor peptide from the hormone calcitonin, is raised in bacterial infections. In the absence of infection, the production of PCT is restricted to predominantly the C-cells of the thyroid, where it is cleaved to form calcitonin and stored in secretory granules. In contrast, bacterial infection leads to a constitutive release of PCT from all the parenchymal tissues of the body, causing a vastly increased serum level. The upregulated calcitonin gene expression is thought to be mediated by the microbial toxins themselves, or via the cytokines (e.g., tumor necrosis factor-α (TNFα)) of a cell-mediated or antibody host response. Its sensitivity for defining a bacterial infection is further increased by the downregulation of calcitonin gene expression by cytokines related to a viral infection (e.g., interferon-γ). 14 Although defining a gold standard for infection is difficult, as even a positive blood culture has low sensitivity, a recent meta-analysis assessed the performance of PCT and other commonly used markers of infection and inflammation in detecting a bacterial infection. PCT was found to be more sensitive (88% vs 75%) and specific (81% vs 67%) than CRP in bacterial infection. 3 It has a superior negative predictive value and is not attenuated by immunosuppressants. Furthermore, PCT has a more favorable temporal profile than other inflammatory markers, with a peak increase at 8 h after infection as opposed to the peak of CRP at 36 h. 3 The problems with the lack of a suitable gold standard for a bacterial infection in respiratory medicine have led to outcome studies following PCT-directed management. These have been performed in lower respiratory tract infection, 15 community-acquired pneumonia, 16 and more recently chronic obstructive pulmonary disease (COPD). 17 In these studies, the level of PCT (level <0.1 μg/L antibiotics strongly discouraged, <0.25 μg/L discouraged, >0.25 μg/L encouraged, >0.5 μg/L strongly encouraged) was used to decide whether antibiotics should be given on a daily basis. The outcome of the PCT-directed treatment group was compared with a matched control group that was treated according to usual practice with respect to antibiotic usage and clinical outcomes. The authors showed a significant reduction in antibiotic use with no change in clinical outcomes.
We hypothesized that PCT could also be effective as a marker in bronchiectasis. For exacerbations, it would help to define the group of patients with evidence of bacterial infection that required intravenous antibiotics, and by following the level of PCT, the length of antibiotic course could also be individually designed. Similarly, in the outpatient department, we suggested it could be used in helping to define the group of patients needing oral antibiotics for exacerbations. We also hypothesized that the patients who would be most at risk of repeated exacerbation would have increased bacterial loads in their respiratory tracts. If these patients could be detected by elevated PCT levels, this marker may be used in helping to define a subgroup of patients that could benefit from long-term prophylactic antibiotics. This study was a descriptive cohort study looking at this new marker in both the stable and exacerbating states compared with other markers to inform future studies of their possible roles in guiding management.
Methods
The study was conducted at the Royal Brompton Hospital between January and May 2006 in patients with bronchiectasis and received ethical committee approval. Thirty-eight consecutive inpatients and 63 consecutive outpatients consented and were included. All patients had routine blood test (full blood count, urea + electrolytes, CRP, ESR) including PCT, and a symptom score was recorded. Inpatients had these values repeated at day 5 and 10. Outpatients also had alveolar nitric oxide (aNO) measurements. Patients were treated according to usual practice. Outpatient's records were reviewed to look for admissions because of exacerbations over the next 3 and 6 months following the PCT assessment. PCT was measured with the BRAHMS PCT Sensitive LIA immunoluminescent assay (sens 0.01 μg/L) and compared with the other inflammatory markers, and the patient's symptom score (0-10 visual analogue scale). Nitric oxide (NO) was measured at 30, 50, 100, and 200 mL/s using a chemiluminescence analyzer (NiOx, Aerocrine, Sweden). aNO was calculated according to the Trumpet model with axial diffusion. 18 Statistical analysis was performed on SPSS using Mann-Whitney (MW), Spearman's correlation, chi-squared and repeated measurement ANOVA tests.
Results
All patients had bronchiectasis defined by highresolution computed tomography (HRCT) criteria. The aetiologies of bronchiectasis were similar in the inpatient and outpatient groups. Idiopathic (34.6%) and post-infective (24.7%) were the most common causes, with allergic bronchopulmonary aspergillosis (12.3%), primary ciliary dyskinesia (9.9%), and immune deficiency (8.6%) making up the majority of the remainder. These were in accordance with previous studies of bronchiectasis aetiologies. 19 The inpatient group probably reflected a population with more severe bronchiectasis as judged by the greater number of lobes affected on HRCT scan (mean 5.42 vs 4.09) ( Table 1) . A significantly greater proportion of inpatients (81.6%) also had chronic Pseudomonas aeruginosa infection as compared with the outpatient group (36.5%). The sputum culture growths are shown in Table 2 . Prophylactic antibiotics were used by a similar percentage of patients in the inpatient and outpatients groups.
The PCT concentrations (and other inflammatory markers) were significantly higher in the inpatient group than in the outpatient group (Figure 1 ). Despite this, the majority of PCT concentrations in the patients admitted for intravenous antibiotics were <0.1 μg/L (median 0.055), a value used in other studies to indicate bacterial infection was unlikely to occur. These levels remained relatively consistent during measurements throughout the admission, and there was no significant difference in PCT concentrations between the measurements at days 0, 5, and 10 using a repeated measurement ANOVA (P = 0.204). There was no significant correlation between PCT and the other inflammatory markers in the inpatient group. As expected, the inpatients experienced more symptoms and felt less unwell than the outpatients, most of whom had routine appointments. In the outpatient group, PCT concentrations were generally very low. They were raised (>0.1 μg/L) in only six patients. There was no significant difference in PCT levels in the outpatients who had no intravenous antibiotics for 3 months and no oral antibiotics for 6 weeks as compared with those who had received antibiotics within these timeframes (PCT mean 0.03 μg/L (standard 0.042) vs 0.024 μg/L (0.034)). In this group of patients, PCT levels were significantly correlated to CRP (P = 0.03) and aNO (P = 0.008) but not other serum markers. High PCT concentrations tended to high levels of symptoms (P = 0.09).
Seven patients were prescribed antibiotics in the outpatient appointment for a presumed infective exacerbation. Of these seven, three patients had a raised PCT (>0.1)which was 50% of patients in which a raised PCT was found. In contrast, only four antibiotic prescriptions (7%) were given in the 57 patients with a normal PCT. This significant difference (P = 0.007) suggests that patients with a high PCT in outpatients were much more likely to be diagnosed as having an infection (Figure 2) .
Twelve of the 63 outpatients were admitted to hospital over the next 6 months for intravenous antibiotics to treat infectious exacerbations. There was no relationship between the original PCT level and the likelihood of re-exacerbating (P = 0.884 Mann-Whitney).
Discussion
The purpose of this study was to investigate PCT concentrations in patients with bronchiectasis in outpatients and inpatients requiring intravenous antibiotics, to determine its potential in guiding management decisions. PCT concentrations were generally low and in most cases negative in patients admitted for infective exacerbations. In the recent paper assessing PCT levels in patients with COPD, the concentrations were also low with a median of 0.096 μg/L. 17 This relates more closely to the median in this study (0.055 μg/L) than the concentrations typically seen in pneumonia (median 0.5 μg/L). This may reflect the fact that in both COPD and bronchiectasis, inflammation and infection is commonly confined to the mucosal surface of the airway. In view of this, and the poor pulmonary reserve in patients with COPD, the authors suggested a cut-off level of <0.1 μg/L to advise withholding of antibiotics in acute exacerbations of patients with COPD, as opposed to the 0.25 μg/L cut-off in patients with pneumonia or lower respiratory tract infections.
In the present study, PCT concentrations were low in the inpatients admitted for treatment of an acute exacerbation, with only eight patients (21.1%) having a value in excess of 0.1 μg/L on admission. This compares to 49% in the COPD study. 17 These results suggest that either PCT is a poor biomarker for infective exacerbations of bronchiectasis, probably because of compartmentalized infection within the bronchial lumen, or most patients admitted with symptoms of an acute exacerbation (increased production or purulence of sputum in conjunction with increased malaise and morbidity) do not have a significant bacterial infection. Neutrophilic inflammation in bronchiectasis can be self-perpetuating, and anti-inflammatory treatment may be beneficial. 2, 4 Further, randomized studies, similar to those reported in pneumonia and COPD, looking at outcomes following PCTdirected antibiotic management would be needed to distinguish between these possibilities. In the inpatient group, PCT concentrations did not correlate with the other inflammatory markers. This may be due to the different time courses of the various inflammatory markers. 3 A possible confounding factor in this study is that patients may have taken oral antibiotics before being admitted. Standard bronchiectasis care involves the prompt treatment of infections, and with this in mind, patients are often given courses Figure 2 Antibiotic use related to procalcitonin concentration. On retrospective analysis, outpatients with a high procalcitonin concentration (>0.1 μg/L) were more likely to have been prescribed antibiotics during the outpatient consultation than those with procalcitonin <0.1 μg/L (P = 0.007 χ 2 ). of oral antibiotics to take at home. However, the purpose of this study was to assess the possible use of PCT within the context of normal bronchiectasis care, and hence this study is no less valid for allowing self-treatment before hospital admission. Furthermore, the large cohort of patients with chronic P. aeruginosa colonization means that many of the inpatients will not have an oral antibiotic option. Nevertheless, a similar study excluding patients who had taken antibiotics before admission and PCT measurement would be of interest.
The significantly higher levels of P. aeruginosa in the inpatients could signify that patients with P. aeruginosa infection are more likely to have an increased severity of infection. Pseudomonas aeruginosa colonization has been shown to be related to a progression of disease with an increased rate of decline of lung function, and this pathogen is also associated with a worse quality of life. 20 However, this pathogen may be a marker of more severe disease instead of a cause for progression. 2, 21 Furthermore, the presence of P. aeruginosa reduces the number of oral agents for outpatient management, and hence this population are likely to be selfselecting for intravenous, inpatient management.
In the outpatient group, PCT seemed to be of value as a marker of patients with higher levels of symptoms and was able to signal who was prescribed antibiotics when reviewed retrospectively. PCT correlated only with CRP but not with the other inflammatory markers and suggests the possibility that PCT may be able to give additional information related to a patient's condition. There was no correlation of PCT with outcomes, measured by hospital admissions for acute exacerbations over the next 3 or 6 months. Consequently, PCT does not seem to be a marker that is able to predict those patients likely to exacerbate who may benefit from prophylactic antibiotics.
Conclusion
PCT levels may give further information to commonly used inflammatory markers in bronchiectasis. Values were generally not correlated to other markers. In outpatients, PCT was associated with how the patients felt and antibiotic prescriptions. PCT values were higher for patients admitted for intravenous antibiotics. Nevertheless, values of PCT were generally low (as with other markers), which may reflect the fact that infection and inflammation in bronchiectasis is often confined to the air-way lumen, whereas these markers assess systemic inflammation. Larger studies assessing the role of these markers are needed. However, our cohort study, the first to our knowledge assessing PCT in bronchiectasis, suggested that PCT is less likely to be able to guide treatment of an exacerbation in bronchiectasis than in other causes of a lower respiratory tract infection.
